YY2201 / JiangsuYayo Biotech - LARVOL DELTA

A Dose-escalation Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YY2201 in Patients with Advanced Solid Tumors (ChiCTR) - P1 | N=42 | Not yet recruiting | Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

New P1 trial • Oncology • Solid Tumor

Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Jiangsu YaYao Biotechnology Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor. (PubMed, J Med Chem) - "YY2201 shows superior in vivo anticancer efficacy and a better therapeutic index compared to AZD6738 in a lung cancer xenograft model. YY2201 also exhibits potent cancer suppression effects in combination with chemotherapy in vivo. Currently, the investigational new drug application of YY2201 has been approved by the FDA for further clinical investigation."

Journal • Lung Cancer • Oncology • Solid Tumor